Insights from 2025 ASCO® GU Annual Meeting

Bladder & Urothelial Cancer

1013 views 75 hours watched
05:34

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Perioperative Sacituzumab Govitecan + Zimberelimab + Domvanalimab in Cisplatin Ineligible MIBC Patients - PRISMA-1 Study

FEATURING Ignacio Durán
  • 27 views
  • April 9, 2025
15:16

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Active Surveillance vs. Definitive Local Therapy for Bladder Cancer Patients Showing cCR Following Neoadjuvant Treatment

FEATURING Marie-Pier St-Laurent
  • 42 views
  • March 25, 2025
  • 1
17:17

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Targeting Bladder Cancer With Antibody-Drug Conjugates

FEATURING Maria Jiang
  • 45 views
  • March 11, 2025
17:38

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Summary: The Changing World of NMIBC

FEATURING Bogdana Schmidt
  • 67 views
  • February 26, 2025
08:11

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Adjuvant Nivo vs. Placebo in High-Risk MIUC - Updated Efficacy and OS Data in MIBC From CheckMate 274

FEATURING Matthew Milowsky
  • 84 views
  • February 26, 2025
  • 1
10:18

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Neoadjuvant Durvalumab + Chemo in Operable High-Risk UTUC - iNDUCT Trial

FEATURING Nadine Houede
  • 44 views
  • February 25, 2025
  • 1
18:14

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Summary: The Promise of ADCs in Combination Therapies for Advanced/Metastatic Urothelial Cancer

FEATURING Terence Friedlander
  • 161 views
  • February 24, 2025
  • 1
09:00

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Retreatment With EV/Pembro or ICI After Prior ICI in Advanced Urothelial Cancer - UNITE & KEYNOTE Analysis

FEATURING Vadim Koshkin
  • 154 views
  • February 24, 2025
  • 1
10:07

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: The Role of ctDNA in Improving Clinical Staging for Upper Tract Urothelial Carcinoma

FEATURING Roger Li
  • 22 views
  • February 24, 2025
09:01

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Summary: Perioperative Strategies in MIBC - Key Trial Insights Including CheckMate 274, NIAGARA, and RETAIN-2

FEATURING Elizabeth R. Plimack
  • 247 views
  • February 20, 2025
04:41

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: ABLE-32 Trial - Evaluating Nadoferogene Firadenovec (NADO) for Recurrence Prevention in Intermediate-Risk NMIBC

FEATURING Neal Shore
  • 120 views
  • February 19, 2025
  • 2